Atossa Therapeutics Inc (ATOS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.52-0.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ATOS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||
| Revenues | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.6 | 0.5 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.6 | 0.5 |
| Cost of Revenues | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.1 | 0.0 | 0.3 | 0.0 |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | (0.1) | (0.1) | 0.0 | 0.1 | 0.4 |
| Operating Expenses & Income | |||||||||||||||
| R&D Expenses | 21.2 | 21.2 | 14.1 | 17.3 | 15.1 | 9.2 | 6.6 | 6.6 | 4.2 | 2.3 | 0.8 | 2.4 | 1.1 | 1.1 | — |
| Operating Income | (39.3) | (37.1) | (27.6) | (31.4) | (27.7) | (20.5) | (14.6) | (17.3) | (11.4) | (7.6) | (8.0) | (12.8) | (12.2) | (10.8) | (5.1) |
| Earnings from Continuing Operations | |||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | 1.5 | 2.4 | 4.1 | 4.3 | 0.9 | 0.0 | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | 0.0 | 1.6 | 0.0 | — | — | — |
| EBT, Incl. Unusual Items | (37.7) | (34.8) | (25.5) | (30.1) | (27.0) | (20.6) | (17.8) | (17.2) | (11.4) | (8.1) | (6.4) | (12.8) | (12.2) | (10.8) | (5.1) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||||||||
| Net Income | (37.7) | (34.8) | (25.5) | (30.1) | (27.0) | (20.6) | (17.8) | (17.2) | (11.4) | (8.1) | (6.4) | (15.8) | (14.7) | (10.8) | (5.1) |
| Per Share | |||||||||||||||
| Basic EPS | (4.23) | (4.04) | (0.20) | (0.24) | (0.21) | (0.18) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (4.23) | (4.04) | (0.20) | (0.24) | (0.21) | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 8.9 | 8.6 | 125.9 | 126.1 | 126.6 | 117.0 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 8.9 | 8.6 | 125.9 | 126.1 | 126.6 | — | — | — | — | — | — | — | — | — | — |
| Supplemental | |||||||||||||||
| EBITDA | — | — | — | — | (27.7) | (20.5) | (14.6) | (17.2) | (11.4) | (7.5) | (7.7) | (12.5) | (11.7) | (10.3) | (4.9) |
| EBIT | (39.3) | (37.1) | (27.6) | (31.4) | (27.7) | (20.5) | (14.6) | (17.3) | (11.4) | (7.6) | (8.0) | (12.8) | (12.2) | (10.8) | (5.1) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | 0.0% | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.